Response to Birbeck et al.
Wright
Edwina
E
Brew
Bruce J
BJ
Lal
Luxshimi
L
Ali
Sophaginine Ty
ST
Arayawichanont
Arkhom
A
Imran
Darma
D
Kamarulzaman
Adeeba
A
Kongsaengdao
Subsai
S
Kruy
Lim
L
Merati
Tuti Parwati
TP
Samintharapanya
Kanoksri
K
Sarim
Chel
C
Tau
Goa
G
Thangsing
Chinkholal
C
Vin-Samnang
Charlie
C
Wesselingh
Steven L
SL
D000163:Acquired Immunodeficiency Syndrome / Q000188:drug therapy* / Q000453:epidemiology; D017954:Africa South of the Sahara / Q000453:epidemiology; D044966:Anti-Retroviral Agents / Q000009:adverse effects / Q000627:therapeutic use*; D000927:Anticonvulsants / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D015897:Comorbidity; D003431:Cross-Cultural Comparison; D003577:Cytochrome P-450 Enzyme System / Q000187:drug effects / Q000378:metabolism; D004347:Drug Interactions; D004790:Enzyme Induction / Q000187:drug effects; D004827:Epilepsy / Q000188:drug therapy* / Q000453:epidemiology; D015658:HIV Infections / Q000188:drug therapy* / Q000453:epidemiology; D006801:Humans; D019829:Nevirapine / Q000009:adverse effects / Q000627:therapeutic use; D010634:Phenobarbital / Q000009:adverse effects / Q000627:therapeutic use
D044966:Anti-Retroviral Agents; D000927:Anticonvulsants; D003577:Cytochrome P-450 Enzyme System; D019829:Nevirapine; D010634:Phenobarbital